NCT06173518View on ClinicalTrials.gov

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

AUTO1

Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells

Trial Locations (8)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

78229

RECRUITING

Methodist Children's Hospital, San Antonio

84113

RECRUITING

Primary Children's Hospital, Salt Lake City

Unknown

RECRUITING

Hospital Vall d'Hebron, Barcelona

RECRUITING

Hospital Nino Jesus, Madrid

RECRUITING

Great Ormond Street Hospital for Children NHS Foundation Trust, London

RECRUITING

Royal Manchester Children's Hospital, Manchester

RECRUITING

Great North Children's Hospital, Newcastle upon Tyne

All Listed Sponsors
lead

Autolus Limited

INDUSTRY